These findings suggest that understanding the intricate regulatory networks involving METTL3, BRD4, and HSP47 may provide valuable insights into the molecular underpinnings of GC and potentially reveal novel therapeutic targets. The gene discussed is METTL3; the disease is gastric cancer.